- Sektör: Government; Health care
- Number of terms: 6957
- Number of blossaries: 0
- Company Profile:
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for ...
An extracellular protein that has four high affinity binding sites for biotin. Streptavidin is widely utilized in fluorescence microscopy applications due to the ease with which a conjugate fluorescent moiety can be coupled to the protein.
Industry:Pharmaceutical
An extract derived from the mushroom Coriolus versicolor, containing polysaccharide K (PSK) and polysaccharide-peptide (PSP), with potential immunomodulating and antineoplastic activities. Coriolus versicolor extract has been shown to stimulate the production of lymphocytes and cytokines, such as interferons and interleukins, and may exhibit antioxidant activities. However, the precise mechanism of action(s) of this agent is unknown.
Industry:Pharmaceutical
An extract made from the dried leaflets on the pods of Cassia angustifolia or Cassia acutifolia with cathartic activity. Dimeric glycosides in dried senna extract are converted to the active monoanthrones by bacterial action in the colon. Through direct effects on enterocytes, enteric neurons, and muscle, monoanthrones produce giant migrating colonic contractions in addition to water and electrolyte secretion. As do other stimulant laxatives, monoanthrones may induce a limited low-grade inflammation in the colon through activation of prostaglandin/cyclic AMP and nitric oxide/cyclic GMP pathways and perhaps inhibition of Na+, K+-ATPase.
Industry:Pharmaceutical
An extract of soybeans enriched in Bowman-Birk inhibitor (BBI), a soybean-derived, 71-amino acid, polypeptide and serine protease inhibitor with potential chemopreventive activity. Bowman-Birk inhibitor contains distinct inhibitory sites for trypsin and chymotrypsin. Although the exact mechanism by which BBI suppresses carcinogenesis is unknown, its antiproliferative activity appears to be linked to the chymotrypsin inhibitory region.
Industry:Pharmaceutical
An extract of the edible mushroom Maitaki, Grifola frondosa, rich in glucan polysaccharides, with potential immunostimulating activity. Upon oral ingestion, Maitaki mushroom extract may promote dendritic cell (DC) maturation, increase interferon gamma (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha) production, and may enhance natural killer (NK) cell activity, thereby amplifying both innate and T cell-mediated immune responses against cancer cells. In addition, this extract may stimulate the production of granulocyte colony stimulating factor (GCSF) and promote hematopoiesis, and may improve the neutrophil count.
Industry:Pharmaceutical
An extract of the flesh from the fruit of Phaleria macrocarpa, an Indonesian herbal medicine, with potential antineoplastic activity. Although the active ingredients and exact components are unclear, gallic acid and its derivatives in DLBS-1425 appear to inhibit the phosphoinositide-3 kinase (PI3K)/protein kinase B (AKT) signaling pathway by reducing PI3K transcription followed by a reduction in AKT phosphorylation. This extract also appears to induce apoptosis through induction of pro-apoptotic genes such as BAX, BAD and PUMA and inhibition of the apoptosis suppressor Bcl-2.
Industry:Pharmaceutical
An extract of the rhizome of the perennial plant Zingiber officinale with potential antineoplastic activity. Ginger extract contains a number of different phenolic compounds, some of which have displayed antineoplastic, anti-inflammatory, and antioxidant activities. This agent also exhibits antiemetic properties.
Industry:Pharmaceutical
An extract prepared from the fruit of Morinda citrifolia, a plant that yields various herbal preparations. Morinda citrifolia fruit juice has antioxidant properties and may prevent tumorigenesis via inhibition of DNA-carcinogen adduct formation.
Industry:Pharmaceutical
An Fc engineered, humanized anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities. Anti-CD19 monoclonal antibody XmAb5574 targets and binds to CD19, thereby depleting and eliminating CD19-expressing B-cells. The modified Fc region of XmAb5574 increases binding affinity to Fc-gamma receptors of effector cells and thereby enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.
Industry:Pharmaceutical
An Fc-engineered monoclonal antibody directed against human CD20 with potential antineoplastic activity. Anti-CD20 monoclonal antibody AME 133v specifically binds to CD20 antigen (B1), preventing mitogen-induced B-cell proliferation; inhibiting B-cell differentiation; and promoting antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis of B cells expressing CD20. The Fc portion of this monoclonal antibody has been engineered to possess a higher binding affinity for variant Fc receptors on T helper cells, resulting in an augmentation of the anti-tumor immune response. Because of Fc engineering, this agent may be significantly more potent than rituximab in inducing B cell-directed ADCC. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development.
Industry:Pharmaceutical
